Staphylococcus lugdunensis infections, filling in the gaps: a 3-year retrospective review from a comprehensive cancer center
- 393 Downloads
Staphylococcus lugdunensis is considered to be more aggressive than other coagulase-negative staphylococci (CoNS). There are gaps in knowledge regarding the importance of isolating S. lugdunensis from different sources and in different patient subsets. Our objective was to describe the spectrum, clinical manifestations, and outcomes of infections caused by S. lugdunensis in patients with cancer.
A retrospective review of all cancer patients from whom S. lugdunensis was isolated in a pure culture from clinically significant sites.
Between 2011 and 2014, 2263 CoNS were isolated, of them 45 S. lugdunensis were isolated in a pure culture and were included in this analysis. Only three patients were neutropenic. Skin and skin structure infections (SSSIs) occurred most often (36 cases) followed by five blood stream infections, one of which had destructive endocarditis and four infections at other sites. Of the 36 SSSIs, 29 were related to surgical or invasive procedures, and six of these involved an implanted medical device. All isolates were susceptible to vancomycin, 98% to levofloxacin and 89% to oxacillin. All patients responded to the therapy.
Cancer patients including those with neutropenia do not appear to have an increased frequency of infections caused by S. lugdunensis. SSSIs are predominant and are often associated with surgical procedures and/or implanted medical devices. Blood stream infections caused by S. lugdunensis are uncommon but may have an increased rate of serious complications such as endocarditis. Nevertheless, these organisms are generally susceptible to multiple classes of antimicrobial agents, and the overall response to therapy is high.
KeywordsStaphylococcus lugdunensis Cancer patients Skin/skin structure infection
Compliance with ethical standards
Conflict of interest
This study was supported in part by the NIH/NCI under award number P30CA016672 and used the Cancer Center Support Grant resources. The authors had a full control of the data, analysis, and writing of the manuscript, and no others had any input.
- 16.Sabe MA, Shrestha NK, Gordon S and Menon V 2014 Staphylococcus lugdunensis: a rare but destructive cause of coagulase-negative staphylococcus infective endocarditis. Eur Heart J Acute Cardiovasc CareGoogle Scholar
- 17.Streit JM, Jones RN, Sader HS, Fritsche TR (2004) Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the sentry antimicrobial surveillance program (north america, 2001). Int J Antimicrob Agents 24(2):111–118CrossRefGoogle Scholar
- 18.Sahm DF, Deane J, Bien PA, Locke JB, Zuill DE, Shaw KJ et al (2015) Results of the surveillance of tedizolid activity and resistance program: in vitro susceptibility of gram-positive pathogens collected in 2011 and 2012 from the United States and Europe. Diagn Microbiol Infect Dis 81(2):112–118CrossRefGoogle Scholar
- 22.Yen TY, Sung YJ, Lin HC, Peng CT, Tien N, Hwang KP et al. 2014 Emergence of oxacillin-resistant staphylococcus lugdunensis carrying staphylococcal cassette chromosome mec type v in central taiwan. J Microbiol Immunol InfectGoogle Scholar
- 24.Tseng SP, Lin YT, Tsai JC, Hung WC, Chen HJ, Chen PF et al. 2013 Genotypes and phenotypes of staphylococcus lugdunensis isolates recovered from bacteremia. J Microbiol Immunol InfectGoogle Scholar
- 28.Zinkernagel AS, Zinkernagel MS, Elzi MV, Genoni M, Gubler J, Zbinden R et al. Significance of Staphylococcus lugdunensis bacteremia: report of 28 cases and Infection. 2008;36(4):314–321.Google Scholar